
About Celmatix
Celmatix is a Healthcare company based in New York (United States) founded in 2009. Fertility decisions are optimized using data analytics and genomics. Celmatix has raised $24.89 million across 7 funding rounds from investors including Regional Economic Development Councils and Topspin Consumer Partners. The company has 27 employees. Celmatix offers products and services including AMHR2 Agonist Program, Oral FSH Receptor Agonist, and JNK Inhibitor. Its focus areas include Life Sciences, Genomics, Applied Genomics and Clinical Genomics. Its legal entity is Celmatix Inc. Its competitors include Invitae, Myriad Genetics and Genome Medical; 2 of its 3 listed competitors have raised funding.
Company details
Celmatix focuses on womens health. It uses predictive analytics and genomics to create products that help in infertility treatment and proactive fertility management. The company offers POLARIS, a cloud- based analytics platform for optimizing a womans fertility by calculating the personal likelihood of success using various fertility treatment options, tailored to a patients clinical metrics. In addition, the company offers Fertilome, an NGS assay that enables women to evaluate present and future fertility potential. Fertilome analyzes 49 different variants in 32 genes, and is specifically aimed at women who plan to freeze their eggs, have children after the age of 35, or have risk factors that affect fertility such as PCOS, depleted ovarian reserve, endometriosis or other endocrine disorders.
- Headquarters New York, United States
- Employees 27
- SectorsHealthcare
- Website celmatix.com
- Social LinkedIn X Facebook Instagram
- Legal Name Celmatix Inc.
- Total Equity Funding$24.89M (USD)
in 7 rounds
- Latest Funding Round$4.5M (USD), Series C
Dec 2017
- Investors
- Employee Count27
Products & Services of Celmatix
Celmatix offers a comprehensive portfolio of products and services, including AMHR2 Agonist Program, Oral FSH Receptor Agonist, and JNK Inhibitor.
Targets ovarian aging and related health issues in women.
Advances infertility therapies through targeted hormone stimulation.
Addresses inflammation and pain in women's health conditions.
Funding Insights of Celmatix
Celmatix has successfully raised a total of $24.89M across 7 strategic funding rounds. The most recent funding activity was a Series C round of $4.5 million completed in December 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $24.89M
- Total Rounds 7
- Last Round Series C β $4.5M
- First Round $806,129
(Feb 2011)
- Investors Count 2
All 7 funding rounds of Celmatix with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2017 | $4.5M | Series C | β | β | |
| Mar 2016 | $4.8M | Series C | β | β | β |
| Aug 2015 | $3.76M | Series C | β | β | β |
| Dec 2014 | $5.51M | Series C | β | β | β |
| Feb 2013 | $4.01M | Series B | β | β | β |
| Feb 2012 | $1.5M | Series A | β | Topspin Consumer Partners | β |
| Feb 2011 | $806,129 | Series A | β | Topspin Consumer Partners | β |
2 investors in total: 2 institutional.
Investors in Celmatix
Celmatix has secured backing from 2 investors, including institutional and venture fund investors. Prominent investors backing the company include Regional Economic Development Councils and Topspin Consumer Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Topspin Consumer Partners is engaged in private equity investments focused on consumer brands. | topspincp.com | Mamaroneck, USA | ||
| regionalcouncils.ny.gov |
Investor details for Celmatix
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Celmatix
20 people are tracked at Celmatix (4 in leadership, 12 in board & advisors, 4 in team); the tracked headcount is 27.
| Name | Role | Group |
|---|---|---|
Charlotte Frank Sage | VP, Clinical Research Operations | Leadership |
Elizabeth (Ellie) Amador | Director of Clinical Research Operations | Leadership |
Piraye Yurttas Beim | Founder & CEO | Leadership |
Caterina Clementi | VP, Biological Sciences | Leadership |
Richard Anderson | Scientific Advisory Board | Board & advisors |
Harald Dinter | Scientific Advisory Board | Board & advisors |
Susan Herbert | Scientific Advisory Board | Board & advisors |
Björn Hock | Scientific Advisory Board | Board & advisors |
Joan-Carles Arce | Scientific Advisory Board | Board & advisors |
Cory Ondrejka | Strategic Advisor | Board & advisors |
David Sable | Director | Board & advisors |
Linda C. Giudice | Scientific Advisor | Board & advisors |
Roger Gosden | Scientific Advisor | Board & advisors |
Mark Wolters | Strategic Advisor | Board & advisors |
Kevin Lynch | Strategic Advisor | Board & advisors |
Steve Winick | Director | Board & advisors |
Adrienne Day | CBO | Team |
Robert O'Connell | Financial Controller | Team |
Stephen Palmer | CSO | Team |
Craig Bolton | General Counsel | Team |
Complete people profiles for Celmatix
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Celmatix
3 dated milestones of Celmatix across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Celmatix is founded.
- Funding First funding round of $806K.
- Funding Latest funding round, Series C, of $4.5M.
Competitors of Celmatix
Celmatix has 3 listed competitors in our database, 2 of them funded. They include Invitae, Myriad Genetics and Genome Medical.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| invitae.com | 2010 | San Francisco, United States | $189.56M | 1,700 | Home-based genetic tests for detecting diseases are provided to individuals. | |
| myriad.com | 1991 | United States | 2,700 | Molecular diagnostics and personalized medicine for cancer are developed. | ||
| genomemedical.com | 2016 | Monterey, United States | $172.98M | 84 | Genomic testing services are provided clinically and directly to consumers. |
Detailed competitors of Celmatix
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Celmatix
Websites that share an audience with Celmatix (celmatix.com).
Websites whose visitors overlap most with Celmatix. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
cincinnatifertility.com | cincinnatifertility.com | 100% | #2,862,129 | β | |
reproductivehealthctr.com | reproductivehealthctr.com | 100% | β | ||
reproductivefacts.org | reproductivefacts.org | 99% | #505,784 | β | |
rmia.com | rmia.com | 98% | #1,683,967 | β | |
okivf.com | okivf.com | 98% | β | ||
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
All 16 similar websites and full traffic analytics for Celmatix
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 16 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Celmatix (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Celmatix
Complete news archive for Celmatix
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Celmatix
Celmatix was founded in 2009 and raised its 1st funding round 2 years after it was founded.
Celmatix is headquartered in New York, United States. It is registered at New York, New York, United States.
Celmatix is a funded company, having raised a total of $24.89M across 7 funding rounds to date. The company's 1st funding round was a Series A of $806.13K, raised on Feb 2011.
Celmatix has 27 employees.
Celmatix focuses on womens health. It uses predictive analytics and genomics to create products that help in infertility treatment and proactive fertility management. The company offers POLARIS, a cloud- based analytics platform for optimizing a womans fertility by calculating the personal likelihood of success using various fertility treatment options, tailored to a patients clinical metrics. In addition, the company offers Fertilome, an NGS assay that enables women to evaluate present and future fertility potential. Fertilome analyzes 49 different variants in 32 genes, and is specifically aimed at women who plan to freeze their eggs, have children after the age of 35, or have risk factors that affect fertility such as PCOS, depleted ovarian reserve, endometriosis or other endocrine disorders.
Celmatix's top competitors include Myriad Genetics, Genome Medical and Invitae.
Celmatix offers AMHR2 Agonist Program, Oral FSH Receptor Agonist, and JNK Inhibitor.
Celmatix has 2 investors. Key investors include Regional Economic Development Councils, and Topspin Consumer Partners.
Celmatix operates through Celmatix Inc..
